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Abstract
Vaccination against hepatitis B virus is an effective and routine practice that can prevent infection. However, vaccine-
induced immunity to hepatitis B varies among individuals. CD4
+ T helper cells, which play an important role in both cellular
and humoral immunity, are involved in the immune response elicited by vaccination. Polymorphisms in the genes involved
in stimulating the activation and proliferation of CD4
+ T helper cells may influence the immune response to hepatitis B
vaccination. In the first stage of the present study, a total of 111 single nucleotide polymorphisms (SNPs) in 17 genes were
analyzed, using the iPLEX MassARRAY system, among 214 high responders and 107 low responders to hepatitis B
vaccination. Three SNPs (rs12133337 and rs10918706 in CD3Z, rs10912564 in OX40L) were associated significantly with the
immune response to hepatitis B vaccination (P=0.008, 0.041, and 0.019, respectively). The three SNPs were analyzed further
with the TaqMan-MGB or TaqMan-BHQ probe-based real-time polymerase chain reaction in another independent
population, which included 1090 high responders and 636 low responders. The minor allele ‘C’ of rs12133337 continued to
show an association with a lower response to hepatitis B vaccination (P=0.033, odds radio=1.28, 95% confidence
interval=1.01–1.61). Furthermore, in the stratified analysis for both the first and second populations, the association of the
minor allele ‘C’ of rs12133337 with a lower response to hepatitis B vaccination was more prominent after individuals who
were overweight or obese (body mass index $25 kg/m
2) were excluded (1
st stage: P=0.003, 2
nd stage: P=0.002, P-
combined=9.47e-5). These findings suggest that the rs12133337 polymorphism in the CD3Z gene might affect the immune
response to hepatitis B vaccination, and that a lower BMI might increase the contribution of the polymorphism to immunity
to hepatitis B vaccination.
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Introduction
Infection with hepatitis B virus (HBV) is a public health problem
that seriously threatens human life. It results in more than half a
million deaths each year, which are caused mainly by the
consequences of the infection, such as chronic hepatitis B,
cirrhosis, and hepatocellular carcinoma [1,2]. Approximately 93
million Chinese people are carriers of HBV, and 300,000 deaths
occur every year in China as a result of HBV infection [3].
Recombinant vaccines against HBV have been used since the
1980s and are an effective method of preventing HBV infection
and transmission. However, 5–10% of healthy adults fail to
produce protective levels of antibody against the hepatitis B
vaccine (anti-HBs).
Physical characteristics such as older age, male gender, higher
body mass index (BMI), and a history of smoking are associated
with a decreased antibody response to hepatitis B vaccination
[4,5,6,7]. An increased dose of the hepatitis B vaccine can induce
stronger immunity [8]. However, a study of twins indicated that
genetic variation accounts for more than 77% of all factors that
influence the individual response to hepatitis B vaccination [9].
Several polymorphisms in genes of the major histocompatibility
complex (MHC) have been reported to be associated with
variations in vaccine-induced immune response [10,11,12,
13,14,15]. Furthermore, polymorphisms in cytokine and cytokine
receptor genes, such as the interleukins (IL)1b [16], IL4 [17], IL4R
[18], IL10 [19], and IL12B [20], are associated with different levels
of immune response to hepatitis B vaccination. It have been also
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influence vaccine-induced immunity against HBV [21].
CD4
+ T helper (Th) cells play an important role in both cellular
immunity, which is mediated by T lymphocytes, and humoral
immunity, which is mediated by B lymphocytes [22]. Further-
more, CD4
+ Th cells are involved in the immune response that is
elicited by vaccination [23,24,25]. Consequently, the activation
and proliferation of CD4
+ Th cells are important steps in the
immune response. The interaction of the T cell receptor (TCR)/
CD3 complex on the surface of CD4
+ Th cells with the MHC-II-
peptide complex on the surface of antigen-presenting cells (APCs),
which is promoted by CD4, triggers the first signal for the
activation of CD4
+ Th cells [26,27,28]. The TCR/CD3 complex
comprises the clonotypic TCR a/b subunits, which recognize the
MHC-peptide complex, and the invariant subunits c, d, e, and f
(CD3G, CD3D, CD3E, and CD3Z), which mediate signal
transduction [29,30]. The CD3 complex is indispensable for the
activation of CD4
+ Th cells, because the signal transduction
depends on immune receptor tyrosine-based activation motifs
(ITAMs) that are found in the CD3 complex [31]. Many changes
in the sequences of the genes for TCR and CD3 molecules can
affect the expression, structure, assembly or signal transduction of
the TCR/CD3 complex, and consequently they have an impact
on the activation of CD4
+ Th cells and then affect the immune
response to vaccination [26]. In addition, completion of the
activation of CD4
+ Th cells requires a second signal that is
initiated by the interaction between costimulatory molecules on
the surface of both APCs and CD4
+ Th cells [32,33,34]. The
interaction between CD28/CTLA4 and the ligand CD80/CD86
is a well-known costimulatory signal that initiates the positive/
negative stimulation of CD4
+ Th cell activation [35,36]. In
addition to the classic costimulatory molecules, others such as
OX40 and its ligand OX40L, CD54 and its ligand LFA-1 (ITGAL
and ITGB2), CD40 and CD40L, and CD58 and CD2 are also
important in regulating the activation of CD4
+ Th cells
[37,38,39,40]. It has been reported that single nucleotide
polymorphisms (SNPs) in the ITGAL gene and haplotypes of the
CD58 and CD44 genes showed significant associations with anti-
HBs levels in a Gambian population [41,42]. However, there is no
available information on the association between polymorphisms
in the genes that encode the subunits of the TCR/CD3 complex
and costimulatory molecules, and immunity induced by the
hepatitis B vaccine in the Chinese Han population.
In the present study, two independent case–control populations
were recruited to evaluate whether polymorphisms in the genes
that encode the subunits of the TCR/CD3 complex and
costimulatory molecules were associated with different outcomes
of hepatitis B vaccine-induced immunity in the Chinese Han
population. The findings suggested that molecules involved in the
activation of CD4
+ Th cells might influence the efficacy of
hepatitis B vaccination, and contributed to a better understanding
of the diversity and complexity of the genetic factors that affect the
efficacy of hepatitis B vaccination. Furthermore, the results might
be helpful in the identification of specific genes for use as targets in
the development of novel and more effective vaccines.
Materials and Methods
Study populations
The present study was conducted in two independent Chinese
Han populations. Participants in the first stage were recruited from
among healthy volunteers in the community in Beijing. A total of
1,600 individuals were recruited initially, in 2007, after written
informed consent had been obtained. Each participant completed
a questionnaire that included questions about demographic
information, smoking history, vaccination history, chronic disease,
and immunosuppressive disease/medications. All individuals were
tested for five markers of hepatitis B using an Abbott i2000
detection kit (Abbott Laboratory, Chicago, IL). Individuals who
were negative for the five markers of hepatitis B were tested further
for HBV DNA and for anti-HCV and anti-HIV. Participants were
excluded if: 1) they were positive for HBV DNA, hepatitis B
surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-HBs,
anti-HBc, anti-HBe, anti-HCV, and/or anti-HIV; 2) they had
been vaccinated previously with any hepatitis B vaccine; 3) they
had a chronic disease, such as diabetes, cancer, or cardio-
cerebrovascular disease, or were undergoing renal dialysis; 4) they
had any immunosuppressive disease or were taking any immuno-
suppressive medication; 5) they were not of Han ethnicity; 6) they
were younger than 18 years. The remaining 599 individuals were
administered three doses of hepatitis B vaccine at 0, 1, and 6
months (3610 mg i.m.; North China Pharmaceutical Co., Ltd.,
Beijing, China). Levels of anti-HBs were measured at 7 months
using the Abbott i2000 detection kit. Participants who showed low
levels of anti-HBs (10–99 mIU/mL) were designated as low
responders, whereas participants who showed high levels of anti-
HBs ($1,000 mIU/mL) were designated as high responders [10].
The definition of low and high responders was based on the level
of anti-HBs 1 month after the third dose of vaccine.
Participants in the second (confirmatory) stage of the study were
recruited from a large hepatitis B vaccination campaign in
Shandong province in 2009. Written informed consent and
completed questionnaires were obtained from all participants.
The exclusion criteria were the same as those for the Beijing study
population. A total of 3985 qualifying individuals remained in the
confirmatory population. They were divided randomly into three
subgroups and administered different recombinant hepatitis B
vaccines (1st group: 3620 mg yeast-derived recombinant hepatitis
B vaccine, GlaxoSmithKline Investment Co., Ltd., UK; 2nd
group: 3620 mg CHO-derived recombinant hepatitis B vaccine,
North China Pharmaceutical Co., Ltd., Beijing; 3rd group:
3610 mg yeast-derived recombinant hepatitis B vaccine, Dalian
Hissen Bio-pharmaceutical Co., Ltd., Dalian.). The vaccination
schedule, the method of detection of anti-HBs, and the definitions
of low and high responders were the same as for the Beijing study
population described above. All low responders were included in
this study, while high responders were selected randomly until a
similar age and gender ratio was attained for the high responder
group as was present in the low responder group. The process of
sample selection were: high and low responders were categorized
into three age groups (19–30 years old, 31–40 years old, and 41–
50 years old), respectively, and then the high responders in each
age group were selected randomly to reach a similar gender ratio
to that of the corresponding low responder age group. The
statistical software SPSS (version 11.0) was used to evaluate the
characteristics of the sample.
The study was performed in accordance with the guidelines of
the Helsinki Declaration and was approved by the Ethics
Committee of the Institute of Basic Medical Sciences, Chinese
Academy of Medical Science.
Selection of candidate genes and SNPs
In the first stage, a total of 111 SNPs in 17 genes were
genotyped. These genes were selected on the basis of their function
in regulating the activation and proliferation of CD4
+ Th cells.
The proteins encoded by the CD3G, CD3D, CD3E, CD3Z, and
CD4 genes are indispensable co-receptors that help T cell
receptors to combine with the MHC-peptide complex and
CD3Z and Immune Response to Hepatitis B Vaccine
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the first signal for activation of CD4
+ T cells. Costimulatory
molecules were selected on the basis of their function in initiating
the essential second signal that stimulates the activation of CD4
+ T
cells. The Tagger Pairwise Tagging protocol in HapMap was used
to select tag SNPs within each gene, using the following conditions:
Chinese Han race in Beijing, China (CHB), r
2.0.8, and a minor
allele frequency (MAF) .0.05 (HapMap Data Rel 24/Phase II,
November 2008, on NCBI B36 assembly, dbSNP b126). Other
SNPs within each gene were chosen on the basis of their probable
functional importance and a MAF .0.05. A full list of the 111
SNPs is given in Table S1. The SNP ID numbers and detailed
sequence information are available at http://www.ncbi.nlm.nih.
gov/SNP/. The SNPs that showed significant P values (,0.05) in
the first stage were further analyzed in the second stage.
DNA amplification and SNP genotyping
Genomic DNA was extracted from peripheral blood using the
phenol–chloroform method. In the first stage, the 111 SNPs were
genotyped using the iPLEX MassARRAY system (Sequenom Inc.,
San Diego, CA, USA). The details of the primer sequences that
were used for genotyping are summarized in Table S1. To
minimize bias in genotyping errors during the first stage, a mix of
samples from high responders and low responders were included
on each plate. The SNPs with P values,0.05 were selected for
follow-up analysis during the second stage using the TaqMan-
MGB (Genecore Biotech Co., Ltd., Shanghai, China) or TaqMan-
BHQ (Sangon Biotech Co., Ltd., Shanghai, China) probe-based
real-time polymerase chain reaction (PCR). The primer and probe
sequences that were used to genotype each SNP during the second
stage are shown in Table S2. Amplification and detection were
conducted using a Bio-Rad iQ5 Multicolor Real-Time PCR
Detection system (Bio-Rad, Hercules, CA). To confirm the
genotyping results from the first stage, 5% of the samples from
Beijing population, selected randomly, were replicated with the
TaqMan-MGB or TaqMan-BHQ probes that were used in the
second stage.
Statistical analysis
A x2 goodness-of-fit test was used to examine whether the
genotype distributions of each SNP conformed to Hardy–
Weinberg equilibrium (HWE) in the whole study population.
The EPI software (version 6.0) was used to calculate the statistical
power. The allele frequencies for each SNP were compared
between the high and low responders using the x2 test. The
genotype distributions of each SNP were calculated using the
Cochran–Armitage trend test; the calculation was conducted with
EPI software (version 6.0). Logistic regression analysis was used to
adjust for confounding factors, such as age, gender, BMI, smoking
history, and vaccines; this analysis was performed using SPSS
software (version 11.0). Linkage disequilibrium of the CD3Z gene
was tested using Haploview (version 4.2). The threshold for
statistical significance was P,0.05.
Results
Demographic characteristics of the two study
populations
Among the 599 participants who were analyzed in the first
stage, 107 individuals showed low levels of anti-HBs (10–99 mIU/
mL) and were assigned to the low responder group, whereas 214
individuals showed high levels of anti-HBs ($1,000 mIU/mL) and
were assigned to the high responder group [10]. Among the 3985
individuals in the second study population, 636 individuals were
low responders (anti-HBs: 10–99 mIU/mL), and 1090 individuals
were selected from among the high responders (anti-HBs
$1,000 mIU/mL) to give a control group that had similar age
and gender ratios to those of the low responder group.
The demographic details of the two study populations are
summarized in Table 1. All of the participants belonged to the
Chinese Han population. In the first study population, age,
gender, BMI, and smoking status differed significantly between the
high and low responders (P,0.05). There were no significant
differences in the demographic characteristics of high and low
responders in the second study population (P.0.05).
Association between SNPs and the immune response to
hepatitis B vaccination
Analysis of the 1
st stage. A total of 111 SNPs were
genotyped during the first stage, but four SNPs were not
genotyped successfully and were excluded from the analysis. Of
the remaining 107 SNPs, the average success rate for genotyping
was 99.1% (ranging from 71.3–100%). Two SNPs had call rates
below 90% and were excluded from the analysis. Hence, 105
SNPs were analyzed in the first stage (Table S3). Conformity to
HWE was analyzed for the whole study population. Of the 105
SNPs, 15 SNPs did not conform to HWE (P,0.05). Among the
321 samples analyzed, 318 samples (99%) had a call rate .90%,
and 144 samples (45%) had a call rate of 100%.
The genotype distributions of the 105 SNPs were compared
between the high responders and low responders and the results
are summarized in Table S3. Four SNPs (rs12133337 and
rs10918706 in the CD3Z gene, rs10912564 in the OX40L gene,
and rs2298209 in the OX40 gene) showed significant associations
with the immune response to hepatitis B vaccination (Table 2).
The SNP rs2298209 is located in the 39-untranslated region (39-
UTR) of OX40, whereas the other three SNPs are tag SNPs
located in intron. The frequency of the minor allele ‘C’ of
rs12133337 in the CD3Z gene was significantly higher in the low
responders than in the high responders [14.0% vs. 7.5%,
P=0.008, odds ratio (OR)=2.02], and the distribution of the
genotypes differed significantly between high responders and low
responders (P=0.009). The frequency of the minor allele ‘T’ of the
other SNP in the CD3Z gene (rs10918706) was significantly higher
in the high responders than in the low responders (P=0.041,
OR=0.68). The frequency of minor allele ‘T’ of rs10912564 in
the OX40L gene was significantly higher in the low responders
than in the high responders (P=0.019, OR=2.60). In addition,
the frequency of minor allele ‘C’ of rs2298209 in the OX40 gene
was significantly higher in the low responders than in the high
responders (P=0.031, OR=1.99). Given that the frequencies of
occurrence of the risk factors described herein ranged from 0.9%
to 49.3%, the present study demonstrated a power to detect an
allelic association of 13.4% to 81.2% with an OR of 2.0 at a
significance level of 0.05.
Logistic regression analysis with an additive model was used to
adjust for the confounding factors. As shown in Table 2, after
adjustment for confounding factors such as age, gender, BMI, and
smoking, three SNPs (rs12133337 and rs10918706 in CD3Z,
rs10912564 in OX40L) remained association with the immune
response to hepatitis B vaccination (P=0.016, OR=1.98;
P=0.020, OR=0.62; P=0.009, OR=3.36, respectively), where-
as the SNP rs2298209 did not show a significant association with
this response.
Analysis of the 2
nd stage. The three SNPs that were shown
to be associated with the response to vaccination in the first stage
of the study (rs12133337 and rs10918706 in CD3Z, rs10912564 in
OX40L) were genotyped in the second stage. The call rate for each
CD3Z and Immune Response to Hepatitis B Vaccine
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responders were included in the second stage. The genotype
distributions of all three SNPs did not deviate from HWE
(P.0.05). A summary of the results of the single SNP analysis in
the second stage is shown in Table 2 and Table S4. Among the
three SNPs, we detected one SNP in the CD3Z gene (rs12133337)
that showed an association with the immune response to hepatitis
B vaccination. The frequency of the minor allele ‘C’ of rs12133337
was significantly higher in the low responders than in the high
responders (11.6% vs. 9.4%, P=0.033, OR=1.28), and the
distribution of genotypes differed significantly between high
responders and low responders (P=0.035). Logistic regression
analysis with the additive model was used to adjust for
confounding factors. As shown in Table 2, after adjustment for
confounding factors such as age, gender, BMI, smoking, and
vaccines, the minor allele ‘C’ of rs12133337 retained its
association with a lower immune response to hepatitis B
vaccination (P=0.037, OR=1.27). These findings were
consistent with the results obtained in the first stage. Next, the
two populations were combined in the analysis, and we observed
that the frequency of the minor allele ‘C’ of rs12133337 was also
significantly higher in the low responders than in the high
responders in the combined sample (12.0% vs. 9.0%, P=0.0028,
OR=1.37).
Further stratified analysis showed that in both the first and the
second stage, the effect of rs12133337 was more evident in
participants who had a lower BMI (,25 kg/m
2), which implicated
that lower BMI might increase the contribution of rs12133337 to
the immune response to hepatitis B vaccination. As shown in
Table 3, after adjustment for confounding factors by the use of
logistic regression with a dominant model, the frequency of the
minor allele ‘C’ of rs12133337 was significantly higher in the low
responders than in the high responders in Beijing population
(P=0.003, OR=3.58). Similar results were observed in Shandong
population (P=0.002, OR=1.65). After the two populations had
been combined, we found that the frequency of the minor allele
‘C’ of rs12133337 was also significantly higher in the low
responders than in the high responders (P-combined=9.47e-5,
OR=1.81).
Given that rs12133337 is in a non-coding region, linkage
disequilibrium of the CD3Z gene was tested using the SNPs
genotyped during the first stage, to assess the functional relevance
of rs12133337. However, no SNP was in linkage disequilibrium
with rs12133337 (Figure S1).
Discussion
Vaccine-induced immunity to hepatitis B is a complex process
that is controlled by numerous factors. In addition to environ-
mental factors and host-related physical factors, genetic variation
also plays an important role in regulating the magnitude of the
immune response to hepatitis B vaccination [9,12]. As described
above, MHC loci have attracted a great deal of attention and many
consistent results for the role of this region in the immune response
to hepatitis B vaccination have been obtained. Furthermore,
polymorphisms in families of cytokine genes have been implicated
in influencing the degree of immune response to hepatitis B
vaccination. However, reports on polymorphisms in other
candidate genes, such as T cell co-receptor and costimulatory
molecule genes that are involved in regulating the activation and
proliferation of CD4
+ Th cells, are limited [41,42].
In the present study, we evaluated two independent case–
control study populations, and found that the SNP rs12133337 in
the CD3Z gene was associated with the immune response to
hepatitis B vaccination in both populations. The SNP rs12133337
is a tag SNP and is located in the first intron of the CD3Z gene on
chromosome 1q22–23. Two known SNPs (rs16859085 and
Table 1. Characteristics of the study populations.
Beijing Shandong
HR n=214 (100%)
b LR n=107 (100%)
c P HR n=1090 (100%)
b LR n=636 (100%)
c P
Age (years)
a 35.267.70 38.266.71 ,0.001 40.167.08 40.666.93 0.12
Gender
Male 81 (37.9) 59 (55.1) 0.003 553 (50.7) 337 (53.0) 0.37
Female 133 (62.1) 48 (44.9) 537 (49.3) 299 (47.0)
BMI (kg/m
2)
a 23.363.44 24.763.57 0.001 24.463.05 24.663.09 0.08
,25 151 (70.6) 55 (51.4) ,0.001 702 (64.4) 382 (60.1) 0.07
$25 63 (29.4) 52 (48.6) 388 (35.6) 254 (39.9)
Smoking
Yes 37 (17.3) 44 (41.1) ,0.001 183 (16.8) 118 (18.6) 0.35
No 177 (82.7) 63 (58.9) 907 (83.2) 518 (81.4)
Vaccines
d
1 - - 408 (37.4) 236 (37.1)
2 - - 368 (33.8) 188 (29.6) 0.09
3 - - 314 (28.8) 212 (33.3)
4 214 (100) 107 (100) -
aValues are mean 6 SD.
bHR: High responder (anti-HBs $1000 mIU/mL).
cLR: Low responder (anti-HBs 10–99 mIU/mL).
dVaccines: 1) Recombinant yeast-derived hepatitis B vaccine, 3620 mg. 2) Recombinant CHO-derived hepatitis B vaccine, 3620 mg. 3) Recombinant yeast-derived
hepatitis B vaccine, 3610 mg. 4) Recombinant CHO-derived hepatitis B vaccine, 3610 mg.
doi:10.1371/journal.pone.0035303.t001
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intron region, and SNPs in the CD3Z gene that were genotyped in
the present study are not in linkage disequilibrium with
rs12133337, which bring out difficulties in functional analysis.
However, it cannot be ruled out that other SNPs might be in
linkage disequilibrium with rs12133337. CD3Z is an important
subunit of the CD3 complex and acts as an amplification module.
Three ITAMs in CD3Z are essential for signal transduction,
whereas the other subunits of the CD3 complex contain only one
ITAM [43]. Phosphorylation of CD3Z at tyrosine residues in the
ITAMs occurs at an early stage after TCR engagement, and this is
important for signal transduction [44]. The abnormal expression
or false assembly of the TCR-CD3 complex can result in T
lymphocyte dysfunction [45]. Experiments with CD3Z-deficient
animals have shown that the stable assembly and expression of
TCR depends on the amount of CD3Z molecules present [46]. It
has been reported that an SNP in the intron of the CD3Z gene
shows an association with rheumatoid arthritis [47], and another
SNP in the intron of the CD3Z gene is associated with systemic
sclerosis [48]. These findings suggest that the CD3Z molecule
plays an important role in immunity. Furthermore, decreased
expression of CD3Z has been detected in patients infected with
HCV [49] and HIV [50], which implies that the CD3Z molecule
might correlate with progression of infectious disease and that
lower expression of CD3Z might result in an impaired immune
response. However, the detailed mechanism of action of the CD3Z
molecule in vaccine-induced immunity is not clear. The SNP
rs12133337 is a genetic marker, and we hypothesize that it might
be in linkage disequilibrium with other SNPs that affect the
expression of CD3Z directly, thus these SNPs might regulate the
expression of CD3Z collectively. Additional study is necessary to
clarify the function of CD3Z in the immune response that is
elicited by hepatitis B vaccination.
A higher BMI might decrease the immune response triggered
by hepatitis B vaccination, and individuals who are overweight or
obese are not easy to produce protective anti-HBs after hepatitis B
vaccination [4,5]. The world health organization (WHO) has
proposed that a BMI $25 kg/m
2 should be defined as overweight
and that $30 kg/m
2 represents obesity [51,52]. In the present
study, we found that in both the Beijing and Shandong
populations, the association of the minor allele ‘C’ of
rs12133337 with a lower response to hepatitis B vaccination was
more prominent after overweight and obese participants had been
excluded. This is consistent with the idea that a lower BMI might
increase the contribution of the SNP to the immune response to
hepatitis B vaccination. However, the strength of the association
identified in the stratified analysis differed between participants
from Beijing and Shandong (OR=3.58 vs. 1.65). We compared
the proportion of low responders among participants from Beijing
and Shandong (17.8% among Beijing participants and 16.0%
among Shandong participants) and found no significant difference.
Therefore, the difference in the strength of association might be a
result of the different sample size, the different demographics, and
the different geographic sources between Beijing and Shandong
populations. Furthermore, we cannot rule out the possibility that
there was a selection bias in our study.
The two populations in the present study showed the effects of
rs12133337 on hepatitis B vaccine-induced immunity. Logistic
regression analysis was performed to adjust for confounding
factors that might have biased the association of the SNP with the
immune response to hepatitis B vaccination. Furthermore, the
influence of chronic disease was controlled by excluding
individuals with chronic diseases from the study. Until now, there
have been a limited number of studies of the associations between
N
o
t
e
:
T
h
e
n
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
f
o
r
e
a
c
h
S
N
P
i
n
t
h
e
1
s
t
s
t
a
g
e
d
i
f
f
e
r
e
d
b
e
c
a
u
s
e
o
f
d
i
f
f
e
r
e
n
t
c
a
l
l
r
a
t
e
s
.
a
H
R
:
H
i
g
h
r
e
s
p
o
n
d
e
r
(
a
n
t
i
-
H
B
s
$
1
0
0
0
m
I
U
/
m
l
)
;
b
L
R
:
L
o
w
r
e
s
p
o
n
d
e
r
(
a
n
t
i
-
H
B
s
1
0
–
9
9
m
I
U
/
m
l
)
.
c
P
-
v
a
l
u
e
s
a
n
d
O
R
(
9
5
%
C
I
)
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
g
e
n
d
e
r
,
B
M
I
,
a
n
d
s
m
o
k
i
n
g
h
i
s
t
o
r
y
u
s
i
n
g
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
.
d
P
-
v
a
l
u
e
s
a
n
d
O
R
(
9
5
%
C
I
)
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
g
e
n
d
e
r
,
B
M
I
,
s
m
o
k
i
n
g
h
i
s
t
o
r
y
,
a
n
d
v
a
c
c
i
n
e
s
u
s
i
n
g
l
o
g
i
s
t
i
c
r
e
g
r
e
s
s
i
o
n
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
5
3
0
3
.
t
0
0
2
T
a
b
l
e
2
.
C
o
n
t
.
CD3Z and Immune Response to Hepatitis B Vaccine
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35303T
a
b
l
e
3
.
S
t
r
a
t
i
f
i
e
d
a
n
a
l
y
s
i
s
o
f
r
s
1
2
1
3
3
3
3
7
e
f
f
e
c
t
s
o
n
t
h
e
i
m
m
u
n
e
r
e
s
p
o
n
s
e
t
o
h
e
p
a
t
i
t
i
s
B
v
a
c
c
i
n
a
t
i
o
n
b
y
B
M
I
.
B
M
I
$
2
5
k
g
/
m
2
B
M
I
,
2
5
k
g
/
m
2
1
s
t
s
t
a
g
e
H
R
n
=
6
3
(
1
0
0
%
)
a
L
R
n
=
5
2
(
1
0
0
%
)
b
P
c
O
R
(
9
5
%
C
I
)
c
H
R
n
=
1
5
1
(
1
0
0
%
)
a
L
R
n
=
5
5
(
1
0
0
%
)
b
P
c
O
R
(
9
5
%
C
I
)
c
T
T
4
8
(
7
6
.
2
)
4
0
(
7
6
.
9
)
0
.
9
8
1
.
0
1
1
3
5
(
8
9
.
4
)
4
0
(
7
2
.
7
)
0
.
0
0
3
3
.
5
8
C
T
+
C
C
1
5
(
2
3
.
8
)
1
2
(
2
3
.
1
)
(
0
.
9
8
–
1
.
1
2
)
1
6
(
1
0
.
6
)
1
5
(
2
7
.
3
)
(
1
.
5
3
–
8
.
3
8
)
2
n
d
s
t
a
g
e
H
R
n
=
3
8
8
(
1
0
0
%
)
a
L
R
n
=
2
5
4
(
1
0
0
%
)
b
P
d
O
R
(
9
5
%
C
I
)
d
H
R
n
=
7
0
2
(
1
0
0
%
)
a
L
R
n
=
3
8
2
(
1
0
0
%
)
b
P
d
O
R
(
9
5
%
C
I
)
d
T
T
3
0
2
(
7
7
.
8
)
2
0
3
(
7
9
.
9
)
0
.
4
3
0
.
8
5
5
9
6
(
8
4
.
9
)
2
9
5
(
7
7
.
2
)
0
.
0
0
2
1
.
6
5
C
T
+
C
C
8
6
(
2
2
.
2
)
5
1
(
2
0
.
1
)
(
0
.
5
8
–
1
.
2
6
)
1
0
6
(
1
5
.
1
)
8
7
(
2
2
.
8
)
(
1
.
2
0
–
2
.
2
7
)
c
o
m
b
i
n
e
d
H
R
n
=
4
5
1
(
1
0
0
%
)
a
L
R
n
=
3
0
6
(
1
0
0
%
)
b
P
d
O
R
(
9
5
%
C
I
)
d
H
R
n
=
8
5
3
(
1
0
0
%
)
a
L
R
n
=
4
3
7
(
1
0
0
%
)
b
P
d
O
R
(
9
5
%
C
I
)
d
T
T
3
5
0
(
7
7
.
6
)
2
4
3
(
7
9
.
4
)
0
.
4
2
0
.
8
6
7
3
1
(
8
5
.
7
)
3
3
5
(
7
6
.
7
)
,
0
.
0
0
1
1
.
8
1
C
T
+
C
C
1
0
1
(
2
2
.
4
)
6
3
(
2
0
.
6
)
(
0
.
6
0
–
1
.
2
3
)
1
2
2
(
1
4
.
3
)
1
0
2
(
2
3
.
3
)
(
1
.
3
4
–
2
.
4
3
)
a
H
R
:
H
i
g
h
r
e
s
p
o
n
d
e
r
(
a
n
t
i
-
H
B
s
$
1
,
0
0
0
m
I
U
/
m
l
)
;
b
L
R
:
L
o
w
r
e
s
p
o
n
d
e
r
(
a
n
t
i
-
H
B
s
1
0
–
9
9
m
I
U
/
m
l
)
.
c
P
-
v
a
l
u
e
s
a
n
d
O
R
(
9
5
%
C
I
)
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
g
e
n
d
e
r
,
a
n
d
s
m
o
k
i
n
g
h
i
s
t
o
r
y
.
d
P
-
v
a
l
u
e
s
a
n
d
O
R
(
9
5
%
C
I
)
w
e
r
e
a
d
j
u
s
t
e
d
f
o
r
a
g
e
,
g
e
n
d
e
r
,
s
m
o
k
i
n
g
h
i
s
t
o
r
y
,
a
n
d
v
a
c
c
i
n
e
s
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
5
3
0
3
.
t
0
0
3
CD3Z and Immune Response to Hepatitis B Vaccine
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35303genetic polymorphisms and the immune response to hepatitis B
vaccination in the Chinese Han population [18,21], and the
sample sizes were not sufficiently large. In the present study, two
populations, one from Beijing (1
st stage) and a second from
Shandong (2
nd stage), were included, and the size of the Shandong
population was sufficiently large to confirm the results obtained
during the first stage.
However, several limitations of our study should be addressed.
The Shandong population was not a strict replicate population
because the demographics, geography, and vaccine regime
differed from those of the Beijing population. Only low and high
responders were included in our association study [10]. A lack of
power caused by the moderate sample size in the first stage
prevented us from assessing genetic effects in non-responders to
hepatitis B vaccination (anti-HBs ,10 mIU/mL). Low responders
(anti-HBs 10–99 mIU/mL) are also at risk of infection with HBV
owing to waning antibody levels, although the minimum level for
clinical protection is accepted to be 10 mIU/mL. It should be
considered that the diversity of individual immune responses and
subsequent decreases in the levels of anti-HBs, as well as possible
errors in the quantitative determination of anti-HBs, might
influence individuals that are actually at risk of infection [53,54].
Furthermore, it has been reported that some countries have
adopted a higher reference level for anti-HBs (e.g., 100 mIU/mL
in the UK) [55]. Association study that focused on the low
response phenotype might contribute indirectly to the prevention
of HBV infection in low responders. Given that our study was
focused on polymorphisms in the genes that encode the subunits of
the TCR/CD3 complex and costimulatory molecules, the SNPs
that have been reported previously within the HLA region and
other genes associated with hepatitis B vaccine-induced immunity
in the Chinese Han population were not included. We cannot rule
out the possibility that these SNPs might also affect the immune
response to hepatitis B vaccination. The different doses and
sources of vaccine that were used in the second study population
might have contributed to different levels of efficacy of
vaccination, and thus might have biased the outcome of the
immune response to hepatitis B vaccine. However, there was no
statistically significant difference in the frequencies of high
responders and low responders in each vaccine group, and logistic
regression analysis was used to adjust for confounding factors and
thus helped to eliminate bias. Owing to the modest size of the
Beijing population, the statistical power in the first stage would
have been decreased for the SNPs with lower MAFs. Thus, the
other genes that were tested in the first study population might also
affect the immune response to hepatitis B vaccination, even
though they did not reach the level of significance. Close family
relatives (parent–offspring pairs and siblings) were excluded from
our study. However, the second-degree or higher relatives might
be present and had an impact on our results. The association
identified in the present study should be validated in other ethnic
populations. The immune response elicited by vaccination is the
cumulative effect of multiple genes in the immune response
network [56]. Therefore, in future studies, greater attention should
be paid to the combined effects of SNPs in different genes on the
efficacy of the immune response to vaccination.
In conclusion, the results of the present study have shown that
the minor allele ‘C’ of rs12133337 in the CD3Z gene is associated
with susceptibility to a lower immune response to hepatitis B
vaccination in the Chinese Han population, and that a lower BMI
might increase the contribution of the polymorphism to this
immune response. These findings suggest that polymorphisms in
the CD3Z gene might affect the outcome of the immune response
to vaccination against hepatitis B. Furthermore, the study suggests
that several novel candidate genes outside the HLA region might
influence the immunity that is induced by vaccination against
hepatitis B. Additional studies that concentrate on the search for
new molecules involved in the immune response to hepatitis B
vaccination might lead to a better understanding of the
mechanism of action of vaccines.
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